Danish Allergic immunotherapy expert Alk Abello (Alkb: DC/OMX: Alk B) has announced that the UK pharmaceutical and medical product regulators (MHRA) have approved 2 mg of Eureneffy for the treatment of anaphylaxis for adults and children.
The UK market launch, which can be seen as an alternative to the Epipen Epinephrine Auto-Injector, is expected in the next few months when the market access negotiations are completed.
The trademark name is NEFFY in the United States, but the European Union and the European Eureffy.
This article can be accessed by registered users and register for free to keep reading. The free trial allows you to access the sharpest monopoly features, interviews, round -ups, and commentary in the sharpest mind in pharmaceutical and biotechnology spaces for a week. If you are already registered users, log in. After the test, you can subscribe here.
Please log in to your account
Try it before purchasing
free
7 days test access
Get a free trial
- All news that moves needles in pharmaceuticals and biotechnology
- Exclusive functions, podcasts, interviews, data analysis and commentary of Global Life Sciences Reporters.
- Receive Pharma Letter Daily News Bulletin forever.
Be a subscriber
£ 820
Or £ 77 a month
Subscribe now
- Access to the industry’s best news, commentary and analysis of pharmaceutical and biotechnology.
- Update of clinical trials, meetings, M & A, license, funding, regulation, patent and law, executive promise, commercial strategy and financial results.
- Daily roundup of major events of pharmaceutical and biotechnology.
- Monthly briefing for the meeting room promises and M & A news.
- Choose from cost -effective annual packages or flexible monthly subscriptions.
Pharma Letter is a very useful and valuable life science service, providing daily updates for performance personnel and products. This is part of the main information to provide information.
Chairman of Sanofi Aventis UK
